Table 4 Adjusted mean FEV₁ and FVC outcomes at 6 weeks (full analysis set)

Study 1222.37

 Placebo

−0.30 (pre-dose/trough)

1.475 (0.017)^a

3.212 (0.037)^b

 Olodaterol 5 μg

1.564 (0.017)^c

0.089 (0.017)

<0.0001

3.319 (0.037)^a

0.107 (0.031)

0.0006

 Olodaterol 10 μg

1.576 (0.017)^c

0.101 (0.017)

<0.0001

3.310 (0.037)^a

0.098 (0.031)

0.0017

 Placebo

60 (post-dose)

1.473 (0.019)^a

3.187 (0.034)^b

 Olodaterol 5 μg

1.698 (0.019)^c

0.224 (0.017)

<0.0001

3.471 (0.034)^a

0.285 (0.029)

<0.0001

 Olodaterol 10 μg

1.699 (0.019)^c

0.226 (0.017)

<0.0001

3.477 (0.034)^a

0.290 (0.029)

<0.0001

Study 1222.38

 Placebo

−0.30 (pre-dose/trough)

1.520 (0.024)^d

3.103 (0.039)^d

 Olodaterol 5 μg

1.630 (0.025)^e

0.110 (0.019)

<0.0001

3.222 (0.040)^e

0.119 (0.036)

0.0013

 Olodaterol 10 μg

1.630 (0.025)^f

0.110 (0.019)

<0.0001

3.222 (0.040)^f

0.119 (0.037)

0.0013

 Placebo

60 (post-dose)

1.577 (0.026)^d

3.144 (0.039)^d

 Olodaterol 5 μg

1.768 (0.026)^e

0.192 (0.021)

<0.0001

3.409 (0.040)^e

0.265 (0.035)

<0.0001

 Olodaterol 10 μg

1.771 (0.026)^f

0.195 (0.021)

<0.0001

3.425 (0.040)^f

0.281 (0.035)

<0.0001